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Circulating tumor cells (CTCs) can be collected from peripheral blood and may provide pharmacodynamic 
information to aid therapeutic decision making.1 Furthermore, 
CTCs as a “virtual and real-time biopsy” have clear potential 
to facilitate exploration of the same prognostic or predictive 
biomarkers as those found in the primary tumor.2,3
The multitarget antifolate agent pemetrexed (PMX) is 
currently administered to patients with nonsquamous non-
small cell lung cancer (NSCLC). PMX primarily targets thy-
midylate synthase (TS), and TS is currently being investigated 
as a predictive biomarker for PMX-based chemotherapy.4,5
In November 2010, a 50-year-old woman was diag-
nosed with metastatic adenocarcinoma of the right lower 
lobe (cT4 cN3 cM1b, epidermal growth receptor factor 
wild type). First-line treatment with cisplatin and PMX was 
scheduled for December 3, 2010. Before administration, we 
collected 20 ml of peripheral venous blood to isolate CTCs. 
Mononuclear cells including CTCs were enriched using a 
modified buoyant density gradient centrifugation method 
in Percoll PLUS solution (GE Healthcare GmbH, Munich, 
Germany). Hematopoietic cells were negatively selected 
from the sample using immunomagnetic beads with anti-
CD15 and anti-CD456 monoclonal antibodies. Epithelial 
tumor cells were enriched using magnetic beads (Dynabead 
Epithelial Enrich, Invitrogen GmbH, Darmstadt, Germany) 
coated with the monoclonal antibody BerEP41 against the 
human epithelial antigen EpCAM.6 The resulting CTC-
enriched cell population was dissolved in ThinPrep CytoLyt 
solution and was centrifuged at 150g for 10 minutes. The 
sediment was dissociated in fixating solution consisting of 
50% ethanol and 50% phosphate-buffered saline-buffered 
formalin. Cells were fixed for a minimum of 20 minutes 
before being mounted on a ThinPrep slide.
TS protein expression was evaluated using the 
BenchMark XT autostainer (Ventana Medical Systems, Inc., 
Tucson, AZ). After pretreatment, CTC containing slides and 
4 m sections from the formalin-fixed paraffin-embedded pri-
mary tumor were incubated for 1 hour at 25°C with a mouse 
monoclonal anti-TS antibody (clone 4H4B1, Invitrogen, 
Carlsbad, CA) and counterstained with hematoxylin for 
4 minutes. Negative control was obtained by using a non-
immunized ready-to-use mouse antibody as the primary 
antibody. Tissue section of colorectal carcinoma served as 
positive control.
Microscopic examination revealed several CTCs with 
varying TS expression ranging from weak to strong (Figures 
1A–C). For estimation of the staining intensities, we compared 
the stained CTCs with TS-stained primary tumors (Fig. 2). In 
addition, a strongly TS-positive CTC adjacent immune mag-
netic beads was detected, whose shape is similar to a dividing 
tumor cell in the late prophase stage of mitosis (Figure 1A). 
This dividing CTC presents chromosome maturation with 
condensed chromosomes, which has rarely been observed in 
CTCs. To the best of our knowledge, this is the first report 
of circulating NSCLC cells in the peripheral blood, most of 
which stained strongly for TS.
As high TS expression is associated with inferior clini-
cal outcome to PMX-based therapy, we followed the clinical 
course of this patient. Until February, she received four cycles 
of combined chemotherapy with cisplatin and PMX result-
ing in a partial response per RECIST. Disease progression 
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was diagnosed in multiple sites on May 9, 2011, which was 
157 days after initiation of treatment and 70 days after the end 
of first-line treatment. The progression-free survival is com-
patible with the median progression-free survival reported in 
a large phase III trial of cisplatin and PMX.7 Despite receiv-
ing four additional lines of treatment (erlotinib, docetaxel, 
gemcitabine/vinorelbine, and mitomycin), the patient never 
achieved a second objective treatment response and showed 
disease progression notably under each line within 6 weeks. 
She was still alive on August 8, 2011.
In conclusion, our report established that immuno-
cytochemical detection of biomarkers in CTCs from the 
peripheral blood of NSCLC patients is feasible, and CTCs act-
ing as a surrogate for tumor biopsies hold promise for “real-
time” monitoring of personalized systemic treatments for lung 
cancer.
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FIGURE 2. Adenocarcinoma cells of the lung from the same 
patient stained with hematoxylin/eosin (HE) or an antibody 
against thymidylate synthase (TS) on a 4-m section of the 
formalin-fixed paraffin-embedded primary tumor. A, HE 
staining. B, TS staining. Magnification 1:1000 (using an oil 
immersion objective).
FIGURE 1. Circulating tumor cells (CTCs) isolated from the peripheral blood of a patient suffering from an adenocarcinoma of 
the lung stained with an antibody against thymidylate synthase (TS). A, Strongly TS expressing CTC which resembles a prolifer-
ating CTC in prophase of mitosis and displays chromosome maturation with condensed chromosomes. B, Weakly TS expressing 
CTC. C, Strongly TS expressing CTC. Magnification 1:1000 (using an oil immersion objective). The shown immunomagnetic 
beads have a diameter of 4.5 m.
